ADMA Biologics (NASDAQ:ADMA) Stock Price Down 5.2%

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) were down 5.2% on Tuesday . The stock traded as low as $17.32 and last traded at $17.42. Approximately 1,205,379 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 3,073,645 shares. The stock had previously closed at $18.38.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Mizuho increased their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald lifted their target price on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Finally, HC Wainwright increased their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Down 5.9 %

The stock’s fifty day moving average is $14.57 and its two-hundred day moving average is $10.18. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $4.03 billion, a PE ratio of -859.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.02) EPS. As a group, analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jerrold B. Grossman sold 136,861 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the sale, the director now directly owns 467,305 shares of the company’s stock, valued at $8,070,357.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the completion of the sale, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. The disclosure for this sale can be found here. Insiders have sold a total of 557,900 shares of company stock worth $9,129,891 over the last 90 days. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of institutional investors have recently modified their holdings of the company. Viewpoint Capital Management LLC boosted its holdings in shares of ADMA Biologics by 18.6% during the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 2,416 shares in the last quarter. Quest Partners LLC bought a new position in ADMA Biologics in the second quarter worth approximately $29,000. Arizona State Retirement System lifted its position in shares of ADMA Biologics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock valued at $689,000 after buying an additional 2,645 shares in the last quarter. Eagle Asset Management Inc. boosted its holdings in ADMA Biologics by 20.2% in the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after buying an additional 4,367 shares during the period. Finally, CWM LLC grew its holdings in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.